[5][7][9] This can be with or without total body irradiation (TBI), as a conditioning treatment prior to allogeneic or autologous hematopoietic progenitor cell transplantation (HPCT) in hematological diseases in adults and children.

[9] Thiotepa is also used with high-dose chemotherapy with HPCT support to treat certain solid tumors in adult and children.

[11] The main side effect of thiotepa is bone marrow suppression resulting in leukopenia, thrombocytopenia and anemia.

In April 2007, the United States FDA designated thiotepa as a conditioning treatment for use prior to hematopoietic stem cell transplantation.

[15] In June 2024, the FDA approved a ready-to-dilute liquid formulation of thiotepa to treat breast and ovarian cancer.